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Available online xxxx Polytrauma (PT) is frequently associatedwith hemorrhagic shock (HS), which increasesmorbidity andmortality.
Although various aspects of HS have been addressed in PT patients, the impact of an additional HS is largely
unknown regarding the development of multiple organ dysfunction associated with disturbed glycocalyx and
barrier function early after trauma.
A prospective, longitudinal, mono-centered, observational study enrolling severely injured patients (Injury
Severity Score, ISS = 38.1 ± 2.6) served for an in-depth analysis of blood (drawn on days 0, 1, 2, 3 and 5) and
clinical data (up to 21 days) of 30 patients who were then stratiﬁed into PT with and without HS.
HS signiﬁcantly enhanced signs of acute organ injury, assessed by increased serum concentrations of novel dam-
age markers. Moreover, indicators of glycocalyx and tight-junction dysfunction were found in PT patients all of
whichwere signiﬁcantly enhanced in co-presence of HS. Thesemarkers revealedmultiple signiﬁcant correlations
with speciﬁc barrier, ﬂuid-balance, coagulation, inﬂammation, and clinical-outcome parameters. Strikingly, mu-
cosa fragments, which affected clotting, could be detected in serum after PT/HS.
The results point to HS as a main driver for glycocalyx and barrier breakdown and suggest novel tools for the
monitoring of organ dysfunction in the early course after PT.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Hemorrhagic shock (HS) is a frequent early event in severely injured
polytrauma (PT) patients and, despite modern damage control and
shock-treatment strategies, HS remains associated with high morbidity
andmortality rates [1,2]. In PT patients and experimental PT settings, HS
has been proposed as an engine of systemic inﬂammation [3], gut-
barrier disruption [3,4], danger-associated molecule pattern (DAMP)
exposure [5], endotheliopathy [6-8], complementopathy and coagulop-
athy [9-12]. All these mechanisms may contribute to the development
of multiple organ dysfunction syndrome (MODS). Although various
proteomic and transcriptomic data sets from PT patients have been an-
alyzed for inﬂammatory and infectious consequences [13,14], mecha-
nisms of the molecular danger response due to HS directing towards
early MODS development remain rather unknown. Concerning thera-
peutic strategies for HS in trauma, novel concepts address not only the
inﬂammatory axes [15] and coagulation network [16,17], but also
focus in particular on the endotheliopathy, e.g. by application of fresh-
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frozen plasma, adiponectin or prothrombin-complex concentrates to
restore the vascular barrier [18,19]. Other treatment approaches
aimed to improve trauma−/HS-induced intestinal hypoperfusion, mu-
cosal ischemia and gut-barrier breakdown and thereby MODS develop-
ment, for example, by the glycosaminoglycan heparan sulfate, which in
addition to exhibiting some anti-coagulatory effects could improve im-
munological functions [20]. Nevertheless, a precautionary approach is
required for novel pathophysiological and therapeutic concepts in
trauma−/HS-induced MODS [21]. Consequently, the organ damage
and barrier reactions after PT require closer discriminative characteriza-
tion in regard to the presence or absence of an additional HS and using
reliable monitoring markers.
2. Materials and methods
2.1. Clinical study design
A subcohort of 30 patients was randomly selected from a prospec-
tive, mono-centered, observational cohort study including a total of
104 patients. Blood was drawn consecutively during the ﬁrst 21 days
after PT when admitted to the University Hospital Zurich (Trauma
Level I Center). The study was carried out in accordance with local and
international guidelines and regulations and the study protocol was ap-
proved by the Cantonal Ethic Commission Zurich (StV 26–2007). All pa-
tients were recruited into the study under informed consent as
approved by the Cantonal Ethic Commission Zurich and international
ethical guidelines (NCT02508272). Enrollment criteria were ISS N 17,
age ≥ 18 y, and time after injury b6 h. A clinico-transcriptomic approach
for septic complications after PT as primary endpoint was recently pub-
lished [13,22]. In the present study, the subcohort was stratiﬁed for
manifest HS [23-25] on day 0 as indicated by at least one of the follow-
ing parameters: base excess b −6 mmol/l, lactate ≥2.5 mmol/l, red
blood cell (RBC) transfusion N2 U, and/or a Trauma Associated Severe
Hemorrhage (TASH) score ≥ 10. The patient stratiﬁcation strategy iden-
tiﬁed n=10 patients without and n=20with signs ofmanifest HS. For
baseline levels, six healthy age- and sex-matched volunteers were in-
cluded after informed and written consent (mean age ± standard
error of the mean (s.e.m.): 43.3 ± 8.3 y; median, min.–max.: 44.5,
18–72; male/female 4/2). All included study patients received standard
treatment based on the guidelines of the German Society of Trauma
(DGU).
2.2. Clinical data
Concurrent to the blood sampling, clinical data were collected pro-
spectively. Corresponding scores were retrospectively determined
from the patients' records. As recently described [13], various scores
were applied: ISS, Glasgow Coma Scale (GCS) [26], Sequential Organ
Failure Assessment (SOFA) score [27], systemic inﬂammation score
[13], and the TASH score [23]. Systemic inﬂammatory response syn-
drome and sepsis were deﬁned in accordance with previously
established guidelines [28-30].
2.3. Enzyme-linked immunosorbent assay analyses of patient samples
Blood from patients and healthy volunteers was centrifuged at
2000×g for 10 min at 4 °C and serum was stored at−80 °C. Samples
were assayed using the following kits for human proteins according to
manufacturers' instructions: FABP2/I-FABP, Lipocalin-2/NGAL,
Angiopoietin-2, Syndecan-1, C-reactive protein, MMP-13, serum albu-
min (all DuoSet ELISA, R&D, Wiesbaden-Nordenstadt, Germany), IL-6
(BD Biosciences, Heidelberg, Germany) CC16 (Clara Cell Protein 16,
Elabscience, Bethesda, MD, USA), Heparan Sulfate (Amsbio, Abingdon,
UK), L-FABP (Hycultec, Beutelsbach, Germany), Claudin-5 (Cusabio, Col-
lege Park, MD, USA), ADM/Adrenomedullin (LifeSpan BioSciences,
Seattle, WA, USA), MUC2 (Aviva Systems Biology, San Diego, CA, USA)
and Sphingosine 1 Phosphate (MyBiosource, San Diego, CA, USA).
2.4. Rotational thromboelastometry (ROTEM) analyses
To assess the impact of dilution by high-volume resuscitation,whole
blood anticoagulated with sodium citrate (Sarstedt, Nuembrecht,
Germany) was drawn from healthy volunteers. The respective hemato-
crit was adjusted to 33% or 25% with Jonosterile (Fresenius Kabi, Bad
Homburg, Germany) and incubated with heparan sulfate (Amsbio,
Abingdon, UK), human recombinant syndecan-1 (R&D) and mucin-2
(Sigma-Aldrich, Darmstadt, Germany) for 30min. The activity of the in-
trinsic pathway (INTEM test) was then analyzed using a ROTEM® delta
device (Tem, Munich, Germany).
2.5. Statistics
Patient characteristics in the two groups were compared using the
Chi-square test in case of categorical variables and using Student's t-
test in case of continuous parameters. Correlation analyses were per-
formed using Pearson ProductMoment Correlation. ROTEM parameters
of blood samples with adjusted hematocrit were compared using one-
way ANOVA followed by Student-Newman-Keuls post-hoc test and
paired t-test. These statistical analyses were performed using SigmaPlot
(Version 11.0, Systat Software, Erkrath, Germany). To evaluate whether
HS signiﬁcantly changed overall plasma values of barrier and organ
molecules during the time course after trauma, we used repeated-
measures ANOVA employing SAS (Version 9.3, SAS, Cary, NC, USA).
We applied no formal statistical test on normality due to their very lim-
ited validity regarding our available sample size [31]. Instead, we
assessed graphically by means of QQ-plotting the model residuals
whether there is suspicion of any severe violation of themodel assump-
tions. Overall, we found no apprehensive deviation from the model as-
sumptions for all the variables tested. The alpha level was 0.05 for all
analyses. Results are presented as mean ± s.e.m.
3. Results
3.1. Patient cohort
When compared to the total cohort of 104 patients described by
Rittirsch et al. [13], the 30 patients in our randomly selected subcohort
were not signiﬁcantly different regarding any demographic parameter
(Table 1). Six age- and sex-matched volunteerswere enrolled as healthy
controls.We stratiﬁed the 30patients into thosewith and thosewithout
clear signs of HS employing established clinical parameters [23-25]:
base excess (b −6 mmol/l), lactate (≥2.5 mmol/l), RBC transfusion
(N2 U on day 0), and/or TASH score (≥10) of which at least one had to
be fulﬁlled to deﬁne HS. All key patient parameters are presented in
Table 1. When comparing the two groups with (n = 20) and without
(n=10) HS, we found that although the ISS was similar in both groups
(38.7 ± 2.8 vs. 36.2 ± 6.3, p=0.54), the Abbreviated Injury Scale (AIS)
of the abdomen/lumbar spine and the maximal SOFA until day 21 were
signiﬁcantly increased in the cohortwithHS (2.8±0.3 vs. 1.1±0.4, p=
0.01, and 10.5±1 vs. 6±1.1, p=0.009, respectively). Furthermore, the
length of stay in the intensive care unit and in the hospital were signif-
icantly longer for patients with HS (19.2 ± 2.8 vs. 5.9 ± 1.3, p = 0.01,
and 34 ± 4.1 vs. 17.2 ± 3.2, p = 0.001, respectively). As expected
from our stratiﬁcation, the data conﬁrmed that HS patients had a higher
initial TASH score (p=0.004), lactate levels (p=0.007) andhematocrit
values (p = 0.013), required more total RBC transfusions (p b 0.001)
and had impaired coagulation as indicated by reduced Quick values
(calculated from the thromboplastin time; lower Quick relates to longer
thromboplastin time) (p= 0.008) compared to patients without man-
ifest HS (Table 1).
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3.2. Markers of organ damage and correlation with clinical parameters
To estimate the effect of HS on organs, we determined the plasma
levels of several markers that are considered to reliably represent
organ function and integrity. Over the course ofﬁve days, HS signiﬁcant-
ly increased CC16 plasma levels as a proposed marker for lung damage
compared to patients without HS (p= 0.0498, Fig. 1a). Although CC16
levels did not correlate with the AIS thorax (Supplementary Table S1),
initial plasma levels were correlated with total RBC units (r = 0.62, p
= 0.001, Fig. 1b) and plasma CC16 on day 1 was associated with the
ﬂuid balance on day 2 (r= 0.65, p b 0.001, Fig. 1c). Plasma neutrophil
gelatinase-associated lipocalin (NGAL) as a marker for kidney injury
was initially similar in both groups, but rose at later time points and
was overall signiﬁcantly higher in HS patients (p=0.0003, Fig. 1d). Fur-
thermore, higher NGAL levels on day 1 were signiﬁcantly correlated
with the AIS abdomen (r=0.66, p b 0.001, Fig. 1e) andwere associated
with increased procalcitonin (PCT) levels on day 3 (r= 0.85, p b 0.001,
Fig. 1f). Intestinal-type fatty acid binding protein (I-FABP) as a marker
for intestinal damage and renal dysfunction was initially increased in
HS patients and, although dropping afterwards, remained higher than
in patients without HS throughout the ﬁve days (p = 0.019, Fig. 1g).
Plasma I-FABP on day 0 positively correlated with lactate levels (r =
0.71, p b 0.001, Fig. 1h) and the ﬂuid balance (r = 0.51, p = 0.008,
Fig. 1j). To evaluate liver damage, we determined plasma liver-type
FABP (L-FABP) and found signiﬁcantly increased levels throughout the
time course in the HS group (p = 0.004), whereas the amount in the
Table 1
Descriptive statistics and comparison of demographic parameters in total cohort and stratiﬁed groups. Statistical comparison of total vs. subcohort and of stratiﬁed groups respectively
shown as p-values (Chi-square test for categorical variables and Student's t-test in case of continuous parameters).
Polytrauma subcohort
(n= 30)
Total cohort (n= 104) vs.
subcohort
Polytrauma without HS
(n = 10)
Polytrauma with HS
(n = 20)
PT + HS vs.
PT
Stratiﬁcation of hemorrhagic
shock
All criteria fulﬁlled:
base excess ≥−6 mmol/l
lactate b2.5 mmol/l
pRBC ≤2 units on day 0
TASH score b 10 points
One or more criteria
fulﬁlled:
base excess b−6 mmol/l
lactate ≥2.5 mmol/l
pRBC N2 units on day 0
TASH score ≥ 10 points
Mean ± SEM;
median (min. –max.)
p-value Mean ± SEM;
median (min. –max.)
Mean ± SEM;
median (min. –max.)
p-value
Demographics
Age [y] 39.9 ± 3.3; 33.5 (18–80) 0.34 44.4 ± 6.3; 44.5 (21–78) 37.6 ± 3.8; 31.5 (18–80) 0.45
Sex [male/total] 21/30 (70%) 0.65 4/10 (40%) 17/20 (85%) 0.011
GCS 11.8 ± 0.8; 13.0 (3–15) 0.9 11.5 ± 1.5; 14 (3–15) 12 ± 0.9; 14 (3–15) 0.93
Traumatic brain injury (GCS ≤
12)
11/30 (36.7%) 0.83 4/10 (40%) 7/20 (35%) 0.789
AIS max. 4.5 ± 0.2; 5 (2–6) 0.06 4.6 ± 0.9; 5 (3–6) 4.5 ± 0.8; 5 (3–6) 0.7
AIS head/neck/cervical spine 2.4 ± 0.4; 2 (0–6) 0.64 2.9 ± 0.9; 3 (0–6) 2.25 ± 0.4; 2 (0–6) 0.45
AIS face 0.6 ± 0.2; 0 (0–3) 0.64 0.3 ± 0.3; 0 (0–2) 0.8 ± 0.2; 0 (0–3) 0.2
AIS thorax/thoracic spine 3.6 ± 0.3; 4 (0–5) 0.09 3.3 ± 0.6; 3.5 (0–5) 3.7 ± 0.3; 4 (0–5) 0.49
AIS abdomen/lumbar spine 2.3 ± 0.3; 2 (0–5) 0.33 1.1 ± 0.4; 1 (0–3) 2.8 ± 0.3; 2.5 (0–5) 0.01
AIS upper/lower extremity 2.6 ± 0.2; 3 (0–5) 0.35 2.3 ± 0.4; 2.5 (0–3) 2.8 ± 0.2; 3 (1–5) 0.23
ISS 38.1 ± 2.6; 36 (17–75) 0.06 36.2 ± 6.3; 35 (17–75) 38.7 ± 2.8; 36 (19–75) 0.54
SOFA score initial 5.3 ± 0.6; 6 (0−11) 0.44 4.6 ± 1.2; 5 (0−10) 5.7 ± 0.7; 6.5 (0–11) 0.4
SOFA score max. 9 ± 0.8; 9 (1–18) 0.13 6 ± 1.1; 6.5 (1−11) 10.5 ± 1; 11 (1–18) 0.009
Outcomes
RISC [% survival] 79.7 ± 4.9; 94.2
(25.5–98.8)
0.50 79.1 ± 10.2; 97.3 (25.9–98.8) 80 ± 5.7; 89.8 (25.5–98.5) 0.52
Survival 77% (7 non-survivors) 0.15 3/10 (30%) 4/20 (20%) 0.542
Hospital length of stay [d] 28.4 ± 3.2; 24.5 (4–82) 0.63 17.2 ± 3.2; 17.5 (4–40) 34 ± 4.1; 36.5 (4–82) 0.01
Intensive care unit length of stay
[d]
15.1 ± 2.24; 12 (2–43) 0.68 5.9 ± 1.3; 4 (2−12) 19.2 ± 2.8; 16 (3–43) 0.001
Allogenic blood transfusions
TASH score [points] 8.6 ± 1; 8 (0−22) 0.94 4.6 ± 0.9; 5 (0–8) 10.5 ± 1.2; 11 (2−22) 0.004
Initial (d0) pRBC transfusion
[units]
5.6 ± 1.2; 2.5 (0−21) 0.33 1.1 ± 0.4; 1 (0–3) 7.9 ± 1.5; 5.5 (0–21) 0.002
Total pRBC transfusion [units] 13.4 ± 2.7; 7.5 (0–66) 0.18 3.8 ± 0.5; 4.5 (0–5) 18.2 ± 3.5; 15.5 (3–66) b0.001
Massive transfusion rate 6/30 (20%) 0.39 0/10 6/20 (30%) 0.053
Infectious complications
Nosocomial infections 19/30 (63.3%) 0.41 4/10 (40%) 15/20 (75%) 0.872
Sepsis 6/30 (20%) 0.57 0/10 6/20 (20%) 0.053
Hemostasis and blood gas analysis
Initial base excess [mmol/l] −3.1 ± 0.5;−2.4
(−9.8–2.0)
0.91 −2.2 ± 0.4;−2.4 (−3.7 to
−0.1)
−3.6 ± 0.7;−3 (−9.8–2) 0.38
Initial lactate [mmol/l] 2.3 ± 0.3; 2.2 (0.7–6.8) 0.95 1.5 ± 0.2; 1.4 (0.7–2.3) 2.7 ± 0.3; 2.5 (1–6.8) 0.007
Initial Quick [%] 60.1 ± 3.7; 59 (22–98) 0.85 73.5 ± 5.7; 70 (48–98) 53.4 ± 4.1; 52.5 (22–95) 0.008
Initial aPTT [s] 40.6 ± 4.5; 33 (22–141) 0.87 29.7 ± 1.5; 29 (22–36) 46.1 ± 6.4; 36.5 (25–141) 0.04
Initial hematocrit [%] 28.9 ± 1.3; 29.8
(10.7–41.9)
0.86 33.5 ± 1.5; 33.7 (24.7–40.9) 26.6 ± 1.7; 26.7
(10.7–41.9)
0.013
Initial temperature [°C] 35.3 ± 0.2; 35 (33.1–38.8) 0.97 35.1 ± 0.2; 34.8 (34.2–36.3) 35.4 ± 0.3; 35 (33.1–38.8) 0.58
P-values b0.05 are bold.
Abbreviations: AIS, Abbreviated Injury Score; aPTT, partial thromboplastin time; GCS, Glasgow Coma Scale; HS, hemorrhagic shock; ISS, Injury Severity Score; pRBC, perfused red blood
cells; PT, polytrauma; RISC, Revised Injury Severity Classiﬁcation; SOFA score, Sequential Organ Failure Assessment score; TASH score, trauma associated severe hemorrhage score.
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group without HS returned to the control value after day 1 (Fig. 1k).
Higher L-FABP on day 1 correlated with lower Quick values (r =
−0.45, p= 0.013, Fig. 1l), but with increased PCT on day 3 (r = 0.80,
p b 0.001, Fig. 1m). Further correlations of organ-damage markers and
clinical parameters until day 3 are listed in Supplementary Table S1.
3.3. Detection of systemic inﬂammation and dilutionmarkers and endothe-
lial barrier and glycocalyx components
In order to evaluate systemic inﬂammation, we detected IL-6 in the
time course after injury and found signiﬁcantly increased
concentrations in the patient cohort with HS (p= 0.001, Fig. 2a). As a
result of massive transfusion, serum albumin was decreased, although
not signiﬁcantly, after HS in comparison to patients without shock or
healthy controls (Fig. 2b). To investigate whether HS exacerbated the
traumatic damage to endothelial integrity with respect to loosening
cell-cell contacts and disruption of the glycocalyx layer, we quantiﬁed
several components in serum samples. Sphingosine-1 phosphate
(S1P), a central regulator of vascular permeability, was decreased in
all patients compared to healthy controls and there was a small differ-
ence between the trauma groups (p= 0.024, Fig. 2c). Matrix metallo-
proteinase 13 (MMP-13) was signiﬁcantly higher in serum from HS
Fig. 1.Organ damagemarkers in the plasma of polytrauma patients and correlation with clinical parameters. Levels of the organ-damagemarkers a, clara cell secretory protein (CC16), d,
neutrophil gelatinase-associated lipocalin (NGAL), g, intestinal fatty acid-binding protein (I-FABP) and k, liver-type fatty acid-binding protein (L-FABP) in plasmaof healthy volunteers and
polytrauma patients without andwith HS. Repeated-measures ANOVA; p b 0.05 indicates signiﬁcantly altered overall plasma values in theHS group compared to polytrauma alone. b, c, e,
f, h, j, l,m, Pearson ProductMoment Correlation of plasma levels of damagemarkers to clinical parameters in polytrauma patientswithout andwithHS. Results are shownasmean± s.e.m.
AIS, abbreviated injury score; RBC, red blood cells; PCT, procalcitonin; r, Pearson correlation coefﬁcient.
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patients (p= 0.001, Fig. 2d) and correlated with heparan sulfate con-
centrations on day 1 (r=0.53, p=0.003, Fig. 2e). Claudin-5, part of en-
dothelial tight junctions that play an essential role in the blood-brain
barrier function, was found at signiﬁcantly increased levels in the plas-
ma of HS patients (p = 0.002) and remained elevated throughout the
5-day observation period (Fig. 2f). Claudin-5 plasma levels positively
correlated with blood lactate levels (r = 0.63, p b 0.001, Fig. 2g), and
high numbers of transfused RBC units on day 0 were associated with
higher claudin-5 levels even 2 days after injury (r = 0.63, p b 0.001,
Fig. 2h). Angiopoietin-2, which is released by activated endothelium
and sensitizes the endothelial cell in an autocrine fashion for inﬂamma-
tory stimuli, was initially at the same level in both groups, but signiﬁ-
cantly increased from day 2 after HS and was overall higher in the HS
group (p=0.004, Fig. 2j). Interestingly, the extent of initial transfusion
of patients (RBC on day 0) appeared to increase angiopoietin-2 even
3 days after trauma, as can be seen by the strong positive correlation
(r= 0.87, p b 0.001, Fig. 2k).
Syndecan-1 as a component of the intravascular endothelial glycoca-
lyx with manifold interactions with coagulatory processes was strongly
increased in patients with HS over the time course of observation (p
Fig. 2. Inﬂammatory markers and regulators of the vascular barrier in patient serum and correlation with clinical parameters. Concentrations of a, interleukin (IL)-6, b, albumin, c,
sphingosine-1-phosphate, d, matrix metalloproteinase-13 (MMP-13), f, claudin-5, and j, angiopoietin-2 in serum of healthy volunteers and polytrauma patients without and with HS.
Repeated-measures ANOVA; p b 0.05 indicates signiﬁcantly altered overall serum concentrations in the HS group compared to polytrauma alone. g, Pearson Product Moment
Correlation of plasma claudin-5 to lactate levels on days 0, 1, 2, 3 and 5. h, serum claudin-5 concentrations of polytrauma patients without and with HS on day 2 correlate with red
blood cell (RBC) units on day 0. k, Pearson Product Moment Correlation of plasma angiopoietin-2 levels on day 3 with RBC on day 0. Results are shown as mean ± s.e.m. R, Pearson
correlation coefﬁcient.
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b 0.0001, Fig. 3a), which was also the case when normalized to plasma
protein (p b 0.0001, Fig. 3b). Higher syndecan-1 levels on day 1were as-
sociatedwith highermaximal SOFA scores (r=0.56, p=0.001, Fig. 3c).
Furthermore, plasma syndecan-1 levels over the course of
the observation correlated signiﬁcantly with the activated partial
thromboplastin time (aPTT) (r = 0.62, p b 0.001, Fig. 3d) and weakly
with plasma NGAL (r = 0.40, p b 0.001, Fig. 3e) and plasma L-FABP
(r= 0.39, p b 0.001, Fig. 3f). When assessing heparan sulfate, we found
only a slight increase in plasma levels of HS patients compared to those
withoutHS (Fig. 3g),whichwas relativized by normalizing to plasma pro-
tein (p = 0.003, Fig. 3h). However, in in vitro experiments performing
ROTEM analyses of whole blood with normal hematocrit (45%), addition
of heparan sulfate dose-dependently altered coagulation parameters, es-
pecially the clotting time (pb 0.05, Fig. 3j). As expected, in vitro simulation
Fig. 3.Markers of barrier breakdown in the plasma of polytraumatized patients in correlationwith clinical parameters and organ damagemarkers and their interferencewith coagulation.
Plasma levels of a, syndecan-1, g, heparan sulfate and k, mucin-2 in plasma of healthy volunteers and polytrauma patients without and with HS. Repeated-measures ANOVA; p b 0.05
indicates signiﬁcantly altered overall plasma values in the HS group compared to polytrauma alone. Plasma concentrations of b, syndecan-1, h, heparan sulfate and l, mucin-2
normalized to plasma protein. Repeated-measures ANOVA; p b 0.05 indicates signiﬁcantly altered overall values in the HS group compared to polytrauma alone. c, Pearson Product
Moment Correlation of plasma syndecan-1 on day 1 with the maximal sequential organ failure assessment score (SOFA max.) of polytrauma patients without and with HS. Pearson
Product Moment Correlation of plasma syndecan-1 with d, the abbreviated prothrombin time (aPTT), e, plasma neutrophil gelatinase-associated lipocalin (NGAL) concentrations and f,
plasma liver-type fatty acid-binding protein (L-FABP) levels of all patients on days 0, 1, 2, 3 and 5. ROTEM clot formation time of citrated blood from healthy volunteers with normal
(45%) or adjusted (33% and 25%) hematocrit after incubation with j, heparan sulfate and m, mucin-2; *, p b 0.05 vs. hematocrit 45% without heparan sulfate, one-way ANOVA; §, p b
0.05 vs. hematocrit 45%without heparan sulfate/mucin-2, one-way ANOVA; #, p=0.005 vs. hematocrit 25%withoutmucin-2, paired t-test. Results are shown asmean± s.e.m. R, Pearson
correlation coefﬁcient.
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of the different hematocrit values determined in our PT cohorts with and
without HS (25% and 33%, respectively) signiﬁcantly prolonged clotting
time and clot formation time (p b 0.05, Fig. 3j andm)whichwasmore ap-
parent, although not signiﬁcant, in the presence of 1000 ng/ml heparan
sulfate (Fig. 3j). Furthermore,mucin-2 derived from the intestinalmucosa
was slightly higher in the plasma of patients with HS assessed per ml
serum (p= 0.067, Fig. 3k) and signiﬁcantly enhanced when normalized
to serum protein (p= 0.0005, Fig. 3l). In vitro, mucin-2 did not change
clotting parameters in amounts detected in patient sera at a normal he-
matocrit, but was able to signiﬁcantly prolong clot formation time when
added to blood with an hematocrit of 25% (p = 0.005, Fig. 3m). Our
main ﬁndings are summarized in Fig. 4.
4. Discussion
The pathophysiological andmolecular danger response following PT
appears aggravated in the presence of HS and remains mechanistically
enigmatic and still rather challenging to treat. Recently, novel markers
have been introduced to evaluate hidden early organ damage and for
rapid detection and reliable monitoring of secondary organ damage as
well as inﬂammatory/infectious and coagulopathic complications.
CC16, NGAL, L-FABP and I-FABP were proposed to estimate the extent
of lung contusion [32], kidney injury [33] and liver and intestinal dam-
age [34], respectively. However, to date it remains unclear to what ex-
tent these proposed organ-speciﬁc markers are inﬂuenced by an
additional HS in the complex setting of PT.
In contrast to reported correlations of CC16 with the volume of
contused lung parenchyma in PT patients [32], the speciﬁcity of CC16
as a marker of lung damage is not supported by the present data.
Other studies showed that higher CC16 may reﬂect a loss of air-blood
barrier integrity [35], which is likely to happen in HS patients.
The central role of the kidneys in shock is evidenced by a study in
N2000 trauma patients of whom N2% developed evident acute kidney
injury (AKI) early after trauma, associated with MODS development in
N75% of patients with AKI and a poor outcome [36]. This is in line with
the early increase in NGAL serum concentrations in our HS cohort.
Since HS-induced hypoperfusion and hypoxia contribute to tubular in-
jury [37], it can be assumed that HS after PT causes early remote AKI
via shock pathomechanisms on a prerenal level. Of note, NGAL values
correlated with AIS abdomen during the early posttraumatic course
even though a primary hit of the kidneys by the inﬂicted trauma force
vector is rare. Therefore, PT-induced remote AKI as a “harbinger of
poor outcome” [36] appears to be induced or aggravated byHS. Further-
more, association of NGAL values with PCT three days after PT may be
due to infectious complications, including septic AKI known to be trig-
gered by both pathogen-associatedmolecular patterns andDAMPs [38].
In regard to abdominal injury markers, L-FABP as a liver-damage
marker [34,39] was increased in manifest HS and, as expected, correlat-
edwith coagulation function and indicators of acute phase infection. In-
testinal barrier dysfunction assessed by serum I-FABP [34] exhibited a
HS-dependent rapid and robust increase in PT patientswhich correlated
with serum lactate and the ﬂuid balance. It is striking that a recent pro-
spective study enrolling severely burned patients stratiﬁed forMODS vs.
no-MODS development showed an almost superimposable I-FABP
course early after burn injury [40]. The data are suggestive of an HS-
driven barrier and organ failure based on intestinal ischemia.
Fig. 4. Proposed role of hemorrhagic shock after clinical polytrauma. Hemorrhagic shock after polytrauma reinforces the inﬂammatory reaction.Massive transfusion due to blood loss leads
to decreased albumin and sphingosin-1-phosphate concentrations, inducing an increase in matrix metalloproteinase 13 (MMP-13) by endothelial cells. MMP-13 can cleave off
components of the endothelial glycocalyx which may interfere with coagulation. Furthermore, intestinal damage leads to the release of mucin into systemic blood with
anticoagulatory features. The breakdown of glycocalyx and endothelial tight junctions (TJ, monitored by serum claudin-5) leads to organ damage in distinct spatial and temporal
patterns which can be monitored by organ-speciﬁc clinical markers. CC16, Clara cell protein 16; I-FABP, intestinal fatty acid-binding protein; IL-6, interleukin-6; L-FABP, liver-type fatty
acid-binding protein; NGAL, neutrophil gelatinase-associated lipocalin; sphingosine-1-P, sphingosine-1-phosphate.
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Of note, after the traumatic hit, the different organs appear to follow
a different time pattern for further organ-injury development as pro-
posed recently [41]. A major driver for (multiple) organ dysfunction is
the breakdown of blood-organ barriers. Recently, we published ﬁrst ev-
idence of circulating tight-junctionmolecules in humans andmice early
after PT [42]. Therefore, plasma claudin-5 was used as a tight-junction
marker and was detected persistently in the PT patients with manifest
HS in contrast to decreasing concentrations in the absence of HS. The
positive correlation between claudin-5 and initial lactate values and
RBC transfusion units may indicate ischemia-induced breakdown of
tight-junction barriers after trauma [4,43].
The endothelium also plays a central role in the pathophysiology
after traumatic HS. In this context, the lipidmediator S1P is not only im-
portant for various immune functions, but in addition critical for vascu-
lar barrier integrity and coagulation [44], and has already been
successfully applied in trauma/HS [20]. Angiopoietin-2 was introduced
as promotor for vascular leakage and inﬂammation and was proposed
to be predictive for septic complications and poor outcome [45]. To
what extent angiopoietin-2 is involved in neoangiogenesis and regener-
ation of damaged tissues after PT/HS is relatively unknown and needs
further investigation. Increased vascular permeability during the time
course following PT and HS has been reported to involve degradation
of the apical glycocalyx of endothelial cells [46], including syndecan-1
as an established biomarker for glycocalyx disruption [7,8,47] and its
fragment heparan sulfate. Mechanistically, a prospective observational
study of N400 severely injured patients (median ISS = 17) suggested
sympathoadrenal activation as an important trigger for the develop-
ment of endotheliopathic consequences, identifying epinephrine as
the only independent predictor for syndecan-1 concentrations generat-
ed from glycocalyx shedding [6]. Because endothelial damage was
strongly associated with thrombelastographic signs of coagulopathy in
a recent prospective sepsis study [47], we assessed the
thrombelastographic features in the presence of heparan sulfate in con-
centrations found in the blood of our PT cohort and under simulated
conditions of hemorrhage- and resuscitation-induced hemodilution
(hematocrit 25%) in comparison to PT without HS (hematocrit 33%) or
healthy conditions (hematocrit 45%). Therefore, the described PT-
induced “autoheparinization” effects [7] of shed glycocalyx structures,
including heparan sulfate, could be worsened in the presence of HS. It
seems that PT/HS-induced MMP-13 release induced by decreased albu-
min/S1P concentrations is responsible for the cleavage of glycocalyx
components off the endothelial cells [48]. Aside from that, following
HS in rodents, pancreatic enzymes appear to disrupt intestinal mucus
layers and thereby play a detrimental role in gut-derived sepsis [49].
Here, we indeed detected mucin-2 in the blood of PT patients when
HS was evident (up to 6000 pg/ml). Furthermore, mucin-2 appears to
prolong clot-formation time in the setting of hemodilution and may
thereby support coagulopathic development after trauma with HS.
In conclusion, the results suggest HS as a forceful driver for glycoca-
lyx, barrier, and organ dysfunction in the early course after PT. In the fu-
ture, early monitoring and detection of barrier failure is needed to allow
for treatment of evident and occult organ damage before ﬁrst manifes-
tation of leakage syndrome and multiple-organ failure.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.jcrc.2017.11.025.
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